Literature DB >> 2826670

Persistent infection of YAC-1 cells by coxsackievirus B3.

Y Cao1, D P Schnurr.   

Abstract

Persistent infection (PI) of YAC-1 cells by coxsackievirus B3 (CBV-3) was characterized. CBV-3 PIs were maintained for 7 months or more, although in two other cases cells were cured of virus at 6 and 6.5 months of PI. The titre of infectious virus peaked during the first week of the infection and then gradually decreased. The proportion of cells producing infectious centres increased to 100% by 48 h after infection, remained at that level up to the seventh day, and then rapidly decreased. Susceptibility to PI by CBV-3 varied widely among 40 clones from uninfected YAC-1 cells as judged by the yield of infectious virus at 6 weeks post-infection. None of the clones was completely lysed by the virus. Clones were not obtained from cells infected for 2 or 7 days. Of six clones obtained from cells infected for 14 days and 24 clones from cells infected for 6 weeks, none was producing virus and all were resistant to reinfection by CBV-3. Six of the clones were serially subcultured and all remained resistant for as long as they were maintained (5 months). During the course of the PI, viral variants which produced smaller plaques and required a longer incubation period for the development of visible plaques replaced the original viral population. Thus the PI involved a carrier culture with a large proportion of resistant cells. The resistant state did not require the continued presence of virus.

Entities:  

Mesh:

Year:  1988        PMID: 2826670     DOI: 10.1099/0022-1317-69-1-59

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Persistent infection of K562 cells by encephalomyocarditis virus.

Authors:  I U Pardoe; K K Grewal; M P Baldeh; J Hamid; A T Burness
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Intracellular viral localization in murine coxsackievirus-B3 myocarditis. Ultrastructural study by electron microscopic in situ hybridization.

Authors:  A Ukimura; H Deguchi; Y Kitaura; S Fujioka; M Hirasawa; K Kawamura; K Hirai
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  Characterization of a YAC-1 mouse cell receptor for group B coxsackieviruses.

Authors:  K H Hsu; R L Crowell
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

Review 4.  A review of the possible mechanisms for the persistence of foot-and-mouth disease virus.

Authors:  E L Woodbury
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

5.  Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution.

Authors:  P E Tam; R P Messner
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Isolation and characterization of HeLa cell lines blocked at different steps in the poliovirus life cycle.

Authors:  G Kaplan; A Levy; V R Racaniello
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  Persistent poliovirus infection of human neuroblastoma cells.

Authors:  F Colbère-Garapin; C Christodoulou; R Crainic; I Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Ultrastructural and replicative features of foot-and-mouth disease virus in persistently infected BHK-21 cells.

Authors:  A Donn; M Castagnaro; A I Donaldson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Non-cytopathic infection of rhabdomyosarcoma cells by coxsackie B5 virus.

Authors:  E Argo; B Gimenez; P Cash
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy.

Authors:  R Wessely; K Klingel; L F Santana; N Dalton; M Hongo; W Jonathan Lederer; R Kandolf; K U Knowlton
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.